JPWO2021134086A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021134086A5
JPWO2021134086A5 JP2022539383A JP2022539383A JPWO2021134086A5 JP WO2021134086 A5 JPWO2021134086 A5 JP WO2021134086A5 JP 2022539383 A JP2022539383 A JP 2022539383A JP 2022539383 A JP2022539383 A JP 2022539383A JP WO2021134086 A5 JPWO2021134086 A5 JP WO2021134086A5
Authority
JP
Japan
Prior art keywords
composition
disorders
anxiety
depression
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022539383A
Other languages
Japanese (ja)
Other versions
JP2023508469A (en
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/067235 external-priority patent/WO2021134086A1/en
Publication of JP2023508469A publication Critical patent/JP2023508469A/en
Publication of JPWO2021134086A5 publication Critical patent/JPWO2021134086A5/ja
Pending legal-status Critical Current

Links

Claims (20)

からなる群から選択される、単離された、実質的に鏡像異性的に純粋な化合物又はその薬学的に許容される塩。 An isolated, substantially enantiomerically pure compound selected from the group consisting of: or a pharmaceutically acceptable salt thereof. によって表される鏡像異性体化合物又はその薬学的に許容される塩であって、鏡像異性体化合物が、少なくとも９０％、少なくとも９５％、又は少なくとも９９％の鏡像異性体化合物を有する鏡像異性体混合物中に存在する、鏡像異性体化合物又はその薬学的に許容される塩。 an enantiomeric compound represented by or a pharmaceutically acceptable salt thereof, wherein the enantiomeric compound has at least 90%, at least 95%, or at least 99% enantiomeric compound; Enantiomeric compounds or pharmaceutically acceptable salts thereof, present in から選択される化合物。 A compound selected from. から選択されるか、又はその薬学的に許容される塩である、請求項１又は２に記載の化合物。 or a pharmaceutically acceptable salt thereof. である、請求項３に記載の化合物。 The compound according to claim 3, which is 請求項１から５のいずれか一項に記載の化合物及び薬学的に許容される賦形剤を含む医薬組成物。 6. A pharmaceutical composition comprising a compound according to any one of claims 1 to 5 and a pharmaceutically acceptable excipient. うつ病、不安うつ病、気分障害、不安障害、又は物質使用障害及びそれに関連する任意の症状又は障害を処置するための医薬組成物であって、請求項１から５のいずれか一項に記載の化合物の前記処置のための有効量を含む医薬組成物。 A pharmaceutical composition according to any one of claims 1 to 5 for treating depression , anxiety depression, mood disorders, anxiety disorders, or substance use disorders and any symptoms or disorders associated therewith. A pharmaceutical composition comprising an effective amount of the described compound for said treatment . うつ病又は不安うつ病を処置するための、請求項７に記載の医薬組成物。 8. A pharmaceutical composition according to claim 7 for treating depression or anxiety depression. からなる群から選択される化合物の鏡像異性体混合物を含む組成物であって、鏡像異性体混合物が、ＮＭＤＡ受容体ＭＫ－８０１部位において、より低い結合親和性を有する鏡像異性体の有意により多い量を有する、組成物。 2. A composition comprising an enantiomeric mixture of a compound selected from the group consisting of: wherein the enantiomeric mixture has significantly more of the enantiomer having a lower binding affinity at the NMDA receptor MK-801 site; A composition having an amount. 化合物が、
からなる群から選択される、請求項９に記載の組成物。 The compound is
10. The composition of claim 9, selected from the group consisting of. からなる群から選択される化合物の鏡像異性体混合物を含む組成物であって、鏡像異性体混合物が、ＮＭＤＡ受容体ＭＫ－８０１部位において、より高い結合親和性を有する鏡像異性体の有意により多い量を有する、組成物。 2. A composition comprising an enantiomeric mixture of a compound selected from the group consisting of: wherein the enantiomeric mixture has significantly more of the enantiomer having a higher binding affinity at the NMDA receptor MK-801 site. A composition having an amount. 化合物が、
からなる群から選択される、請求項１１に記載の組成物。 The compound is
12. The composition of claim 11 selected from the group consisting of. うつ病、不安うつ病、気分障害、不安障害、又は物質使用障害及びそれに関連する任意の症状又は障害を処置するための、請求項９から１２のいずれか一項に記載の組成物。 13. A composition according to any one of claims 9 to 12 for treating depression , anxiety depression, mood disorders, anxiety disorders, or substance use disorders and any symptoms or disorders associated therewith . うつ病又は不安うつ病を処置するための、請求項１３に記載の組成物。 14. A composition according to claim 13 for treating depression or anxiety depression. うつ病、不安うつ病、気分障害、不安障害、又は物質使用障害及びそれに関連する任意の症状又は障害を処置するための組成物であって、
からなる群から選択される、単離された、実質的に鏡像異性的に純粋な化合物又はその薬学的に許容される塩を有効量で含む組成物。 A composition for treating depression , anxiety depression, mood disorders, anxiety disorders, or substance use disorders and any symptoms or disorders related thereto, comprising :
A composition comprising an effective amount of an isolated, substantially enantiomerically pure compound selected from the group consisting of: or a pharmaceutically acceptable salt thereof. うつ病、不安うつ病、気分障害、不安障害、又は物質使用障害及びそれに関連する任意の症状若しくは障害を処置するための組成物であって、
からなる群から選択される化合物を有効量で含む組成物。 A composition for treating depression , anxiety depression, mood disorders, anxiety disorders, or substance use disorders and any symptoms or disorders related thereto, comprising :
A composition comprising an effective amount of a compound selected from the group consisting of : 化合物が、
からなる群から選択される、請求項１５に記載の組成物。 The compound is
16. The composition of claim 15, selected from the group consisting of. によって表される、単離された、実質的に鏡像異性的に純粋な化合物又はその薬学的に許容される塩。 An isolated, substantially enantiomerically pure compound represented by or a pharmaceutically acceptable salt thereof. うつ病、不安うつ病、気分障害、不安障害、又は物質使用障害及びそれに関連する任意の症状又は障害を処置するための組成物であって、
によって表される、単離された、実質的に鏡像異性的に純粋な化合物又はその薬学的に許容される塩を有効量で含む組成物。 A composition for treating depression , anxiety depression, mood disorders, anxiety disorders, or substance use disorders and any symptoms or disorders related thereto, comprising :
A composition comprising an effective amount of an isolated, substantially enantiomerically pure compound represented by or a pharmaceutically acceptable salt thereof . うつ病又は不安うつ病を処置するための組成物であって、
によって表される、単離された、実質的に鏡像異性的に純粋な化合物又はその薬学的に許容される塩を有効量で含む組成物。 A composition for treating depression or anxiety depression, the composition comprising :
A composition comprising an effective amount of an isolated, substantially enantiomerically pure compound represented by or a pharmaceutically acceptable salt thereof.
JP2022539383A 2019-12-26 2020-12-28 Arylcyclohexylamine derivatives and their use in the treatment of psychiatric disorders Pending JP2023508469A (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962953611P 2019-12-26 2019-12-26
US62/953,611 2019-12-26
US202063037044P 2020-06-10 2020-06-10
US63/037,044 2020-06-10
US202063093830P 2020-10-20 2020-10-20
US63/093,830 2020-10-20
PCT/US2020/067235 WO2021134086A1 (en) 2019-12-26 2020-12-28 Arylcyclohexylamine derivatives and their use in the treatment of psychiatric disorders

Publications (2)

Publication Number Publication Date
JP2023508469A JP2023508469A (en) 2023-03-02
JPWO2021134086A5 true JPWO2021134086A5 (en) 2023-12-20

Family

ID=74195194

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022539383A Pending JP2023508469A (en) 2019-12-26 2020-12-28 Arylcyclohexylamine derivatives and their use in the treatment of psychiatric disorders

Country Status (10)

Country Link
US (2) US11344510B2 (en)
EP (1) EP4081301A1 (en)
JP (1) JP2023508469A (en)
KR (1) KR20220131520A (en)
CN (1) CN115190815A (en)
AU (1) AU2020415511A1 (en)
CA (1) CA3165903A1 (en)
IL (1) IL294202A (en)
MX (1) MX2022007994A (en)
WO (1) WO2021134086A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11426367B2 (en) 2018-05-04 2022-08-30 Perception Neuroscience, Inc. Methods of treating substance abuse
IL294202A (en) 2019-12-26 2022-08-01 Gilgamesh Pharmaceuticals Inc Arylcyclohexylamine derivatives and their use in the treatment of psychiatric disorders
KR102567903B1 (en) 2020-02-18 2023-08-18 길가메쉬 파마슈티컬스, 인코포레이티드 Specific tryptamines for use in the treatment of mood disorders
CA3220228A1 (en) 2021-05-25 2022-12-01 Celia MORGAN Ketamine in the treatment of behavioural addictions
IL309576A (en) * 2021-06-25 2024-02-01 Gilgamesh Pharmaceuticals Inc Arylcyclohexylamine derivatives and their use in the treatment of psychiatric disorders
AU2022374097A1 (en) * 2021-10-18 2024-03-14 Clearmind Medicine Inc. 2-fluorodeschloroketamine for treatment of depression, including treatment-resistant depression
WO2023154450A2 (en) * 2022-02-11 2023-08-17 Gilgamesh Pharmaceuticals, Inc. (ampa-pam)-nmda receptor antagonist combination therapy for treatment of mental conditions and disorders
CN115677444A (en) * 2022-10-26 2023-02-03 公安部第三研究所 Isotope drug metabolite marker compound, preparation method and application thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB853775A (en) 1957-09-19 1960-11-09 Parke Davis & Co Pharmaceutical compositions and methods for producing phenylcyclohexane compounds
DE1668550A1 (en) * 1967-09-19 1971-07-22 Parke Davis & Co 2-alkoxyalkylamino-2-phenylcyclohexanone compounds and their acid addition salts and processes for their preparation
US4065573A (en) 1976-06-03 1977-12-27 The Upjohn Company 4-Amino-4-phenylcyclohexanone ketal compositions and process of use
CA1100516A (en) 1976-06-03 1981-05-05 Daniel Lednicer 4-amino-4-arylcyclohexanones and their ketals
CA1105938A (en) 1976-06-03 1981-07-28 Daniel Lednicer 4-amino-4-arylcyclohexanone ketals
AU2003249582B2 (en) 2002-06-21 2006-08-03 Suven Life Sciences Limited Tetracyclic arylsulfonyl indoles having serotonin receptor affinity
MXPA04012836A (en) 2002-06-21 2005-04-25 Suven Life Sciences Ltd Novel tetracyclic arylcarbonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them.
DK1537113T5 (en) 2002-06-21 2011-01-10 Suven Life Sciences Ltd Arylalkyl indoles with serotonin receptor affinity useful as therapeutic agents, processes for their preparation and pharmaceutical compositions containing them
DE10252667A1 (en) 2002-11-11 2004-05-27 Grünenthal GmbH New spiro-((cyclohexane)-tetrahydropyrano-(3,4-b)-indole) derivatives, are ORL1 receptor ligands useful e.g. for treating anxiety, depression, epilepsy, senile dementia, withdrawal symptoms or especially pain
DE10252666A1 (en) 2002-11-11 2004-08-05 Grünenthal GmbH N-piperidyl-cyclohexane derivatives
DE10360793A1 (en) 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclic cyclohexane derivatives
EP1912970A2 (en) 2005-08-10 2008-04-23 Bayer Schering Pharma Aktiengesellschaft Acyltryptophanols for fertility control
EP1956016A1 (en) 2006-12-15 2008-08-13 Bayer Schering Pharma Aktiengesellschaft Bicyclic acyltryptophanols
WO2008071455A1 (en) 2006-12-15 2008-06-19 Bayer Schering Pharma Aktiengesellschaft Bicyclic acyltryptophanols
AU2009228645B2 (en) 2008-03-27 2013-07-18 Grunenthal Gmbh Hydroxymethylcyclohexyl amines
AU2010203461A1 (en) 2009-01-09 2011-07-28 President And Fellows Of Harvard College Fluorine containing compounds and methods of use thereof
AU2010251930A1 (en) 2009-05-27 2011-11-24 Universite Libre De Bruxelles 3-alkyl-5-fluoroindole derivatives as myeloperoxidase inhibitors
TWI582092B (en) 2010-07-28 2017-05-11 歌林達股份有限公司 Cis-tetrahydro-spiro(cyclohexane-1,1'-pyrido[3,4-b]indole)-4-amine derivatives
CN104276993B (en) 2013-07-12 2019-03-15 广东东阳光药业有限公司 Indole derivatives and its application on drug
US20180021326A1 (en) 2016-07-23 2018-01-25 Paul Edward Stamets Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin
US20200030309A1 (en) 2016-09-29 2020-01-30 The Regents Of The University Of California Compounds for increasing neural plasticity
BR112019016489A2 (en) 2017-02-09 2020-04-07 Caamtech Llc compositions and methods comprising a psilocybin derivative
GB201808150D0 (en) 2018-05-18 2018-07-11 Small Pharma Ltd Therapeutic compounds
GB201716942D0 (en) 2017-10-16 2017-11-29 Small Pharma Ltd Therapeutic compounds
WO2019081764A1 (en) 2017-10-26 2019-05-02 Consejo Superior De Investigaciones Científicas (Csic) Combination product for the treatment of neurological and/or psychiatric disorders
EP3505509A1 (en) 2017-12-29 2019-07-03 Université de Liège Methods for the preparation of arylcycloalkylamine derivatives
CN111936127A (en) 2018-02-15 2020-11-13 国立大学法人千叶大学 Agent for preventing or treating inflammatory disease or bone disease, and pharmaceutical composition
CN110343050B (en) * 2018-04-04 2021-09-24 上海键合医药科技有限公司 Aromatic compound and preparation method and application thereof
KR102104953B1 (en) * 2018-04-17 2020-04-27 삼육대학교 산학협력단 Novel ketamine derivatives and a use for preventing or treating depression
TW202026281A (en) 2018-12-12 2020-07-16 西班牙商艾斯提夫製藥股份有限公司 New pyrrolidine-2-carboxylic acid derivatives for treating pain and pain related conditions
BR112021017621A2 (en) 2019-03-07 2021-11-23 Arbormentis LLC Compositions and methods of use comprising substances with neural plasticity actions administered in non-psychedelic/psychotomimetic dosages and formulations
IL294202A (en) 2019-12-26 2022-08-01 Gilgamesh Pharmaceuticals Inc Arylcyclohexylamine derivatives and their use in the treatment of psychiatric disorders
CN112174851A (en) 2020-11-09 2021-01-05 广州万孚生物技术股份有限公司 Fluoroaminoketone hapten, fludrominoketone antigen and preparation method and application thereof
CN113234036B (en) 2021-05-12 2023-07-14 斯莱普泰(上海)生物医药科技有限公司 NMDA receptor antagonists and uses thereof

Similar Documents

Publication Publication Date Title
DE60029139T2 (en) BUPROPION METABOLITE AND METHOD FOR THE SYNTHESIS AND USE THEREOF
JP2012521994A5 (en)
JP2019507781A5 (en)
IL255433B2 (en) (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
JP6595078B2 (en) Aminocarbonyl carbamate compounds
SI8310672A8 (en) Process for the production of cis-4-fenil-1,2,3,4-tetrahydro-1-naphthylamine derivates.
RU2012141951A (en) SIP RECEPTOR AGONIST TREATMENT COURSE
JP2009527462A5 (en)
JP7265990B2 (en) R-ketamine and its derivatives as prophylactic or therapeutic agents for neurodegenerative diseases or cognitive dysfunction
CA2470956A1 (en) 1-alkyl-1-azoniabicyclo[2.2.2]octane carbamate derivatives and their use as muscarinic receptor antagonists
JP2014515351A5 (en)
JP2008538582A (en) Novel therapeutic combinations for the treatment or prevention of psychotic disorders
WO2004060882A1 (en) Cb 1/cb 2 receptor ligands and their use in the treatment of pain
JP2022191257A5 (en)
JP2019529514A5 (en)
JPWO2021134086A5 (en)
JP2019529460A5 (en)
JP2007529492A5 (en)
JP2013530953A5 (en)
JPWO2017131149A1 (en) Tetrahydronaphthalene derivative
JP2001511131A (en) Treatment of premenstrual discomfort
US5055468A (en) Use of bridged tricyclic amine derivatives as anti-ischemic agents
RU2019102757A (en) ETHYNYL DERIVATIVES
JPH06500099A (en) Use of heterocyclic amino-alcohol compounds in the treatment of CNS diseases
JP2020504165A5 (en)